Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Cerenome Q3 2026 Results: Net Loss of $8.66M, Loss Widens

Cerenome, Inc. reported a net loss of $24.6 million for the nine months ended September 30, 2026, compared to a $16.7 million loss in the prior year period. While the company introduced diagnostic revenue of $0.7 million, total revenue decreased due to lower grant revenue, and operating expenses nearly doubled to $25.8 million.

Watch the Cerenome, Inc. earnings callFull call on the ALFA USA YouTube channel
Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.71.4
Net income-8.7-4.4
EPS (diluted, $ a share)$-1.14$-1.03

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-48.3%
Source

10-Q filed with the SEC, NASDAQ: CNSY. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Cerenome, Inc.: key numbers

Share price
$0.7148Close, Nov 16
Market cap
$6.99M
Shares outstanding
9.78MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Cerenome, Inc.

All →
7:45 AM ET 8-K
Clinical Trial Data

Cerenome Clinical Trial Data

Cerenome reported interim data from its Phase 1 ReSPECT-LM study evaluating repeat dosing of REYOBIQ in patients with leptomeningeal metastases. The data showed no dose-limiting toxicities in the first 10 patients and indicated consistent radiation delivery across repeat administrations, with early disease control signals showing no progression in evaluable patients at the six-month landmark.

Counterparty
Society for Neuro-Oncology
4:52 PM ET 8-K
Financial Results

Cerenome Financial Results

Cerenome (formerly Plus Therapeutics) reported Q3 2026 financial results, highlighting its first quarter of CNSide diagnostic revenue totaling $0.7 million. The company expanded its payer coverage to approximately 190 million lives and completed enrollment in its Phase 2 glioblastoma trial. Additionally, the company rebranded from Plus Therapeutics to Cerenome during the quarter.

Term
Q3 2026

“Recognition of our first quarter of CNSide® diagnostic revenue and commercial payments beginning in October is a tremendous landmark. Furthermore, our payer universe continues to expand with now about 80% of U.S. private payers representing approximately 190 million covered lives. Most recently, with Aetna coverage, it gives physicians an in-network option for both tumor cell enumeration and molecular profiling. In parallel, our growing commercial team is focused on helping more cancer centers use our test in patient care. In therapeutics, we materially advanced our two key programs by completing enrollment in our Phase 2 trial in adults with recurrent glioblastoma, opening up higher dose cohorts in the repeat dosing of REYOBIQ™ in patients with leptomeningeal metastases and reporting interim data in that trial.”

Marc H. Hedrick, M.D., Cerenome’s President and Chief Executive Officer
6:01 AM ET 8-K
Executive Compensation

Cerenome Executive Compensation

Cerenome, Inc. appointed Ronald A. Andrews as its new Chief Business Officer, effective November 9, 2026. Mr. Andrews, who already serves on the company's board, entered into an employment agreement providing for an annual base salary of $344,955, a 43% target bonus, and an option to purchase 92,858 shares of common stock.

Counterparty
Ronald A. Andrews
7:31 AM ET 8-K
Investor Presentation

Cerenome Investor Presentation

Cerenome, Inc. (formerly Plus Therapeutics, Inc.) filed an updated corporate presentation as of September 30, 2026, for use in meetings with investors and analysts. The presentation covers the company's clinical trials, strategic collaborations, and the development of its CNSide platform for genomic testing.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.